ArticleCancer cell international2025
LncRNA H19 acts as a ceRNA to promote glioblastoma malignancy by sponging miR-19b-3p and upregulating SERPINE1.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Retinoic Acid and Long Noncoding RNAs Crosstalk: Implications for Neuronal Differentiation and Diseases.Molecular neurobiology · 2026Review
- Long non-coding RNAs in the exosomal network: dual roles and clinical implications in cancer.Animal cells and systems · 2026Review
- Comprehensive ceRNA Profiling Uncovers Clinically Relevant Hub lncRNAs in Glioblastoma.Bioinformatics and biology insights · 2026Article
- Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.Non-coding RNA research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a highly aggressive brain tumor, characterized by genetic complexity and resistance to treatment. Despite significant advancements in cancer research, the mechanisms driving GBM progression remain poorly understood. This study investigates the molecular pathways associated with GBM, and focuses on long non-coding RNA H19 and its role in tumor growth and progression.
methodsAnalysis of Gene Expression Omnibus (GEO) dataset was performed to identify differentially expressed genes in GBM cells with H19 overexpression, revealing serpin family E member 1 (SERPINE1) as a potential target. Bioinformatics analyses were used to evaluate the differential expression of H19 and SERPINE1 in GBM tissues, perform survival analysis, and predict miR-19b-3p as a candidate miRNA. The expression levels of H19, miR-19b-3p, and SERPINE1 were validated using RT-qPCR and Western blotting. Dual-luciferase reporter assays were conducted to confirm the direct interactions between H19, miR-19b-3p, and SERPINE1. Cell viability and motility assays were performed to assess the effects of modulating H19/miR-19b-3p/SERPINE1 expression on cell survival, migration, and invasion.
resultsBioinformatics analyses identified SERPINE1 as an oncogene upregulated in GBM cells with H19 overexpression, and the overexpression of H19 and SERPINE1 was linked to poor prognosis in GBM patients. Experimental validation demonstrated that H19 upregulates SERPINE1 expression, while miR-19b-3p directly binds to both H19 and SERPINE1, suppressing SERPINE1 expression. Functional assays further confirmed that H19 promotes cell survival, migration, and invasion, whereas miR-19b-3p inhibits these processes by downregulating SERPINE1.
conclusionsThese findings reveal a novel mechanism whereby H19 drives GBM progression by acting as a competing endogenous RNA (ceRNA) to sponge miR-19b-3p and upregulate SERPINE1 expression. Our results offer new insights into the regulatory interplay among H19, miR-19b-3p, and SERPINE1 in GBM cell lines, a relationship that has not been clearly defined in previous research. Moreover, the H19/miR-19b-3p/SERPINE1 axis highlights the potential use of H19, miR-19b-3p, and SERPINE1 as promising biomarkers and therapeutic targets in GBM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.